All In Biotech

Drug Trial Radar · NCT05727839

Study to Evaluate JCXH-211 as Monotherapy in Patients With Malignant Solid Tumors

A Phase 1 Open-Label Study to Evaluate the Safety, Tolerability and Efficacy of JCXH-211 Intratumoral Injection in Patients With Malignant Solid Tumors

Last checked: Nov 20, 2026Latest source record: Nov 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

19

Actual

Start

Feb 24, 2023

Primary completion

Sep 30, 2024

Study completion Sep 30, 2024

Sponsor

Lead sponsor
Immorna Biotherapeutics, Inc.Industry
Sponsor type
Industry
First posted
Feb 14, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

: A Phase 1 Open-Label Study to Evaluate the Safety, Tolerability and Efficacy of JCXH-211 Intratumoral Injection in Patients with Malignant Solid Tumors

Conditions

  • Cutaneous Tumor
  • Malignant Solid Tumor

Interventions

  • JCXH-211 InjectionDrug

    JCXH-211 administered once every 28 days or 14days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Dose limiting toxicityTime frame: Within 28 days or 14days after the first dose
  2. Incidence of adverse events (Safety and Tolerability)Time frame: From consent to 28 days after the last dose of study drug

Locations

2 sites in 2 countries. Site status is shown where the registry gives one.

  • The George Washington Medical Faculty Associates

    Washington D.C., District of Columbia

  • Sun Yat-sen University Cancer Center

    Guangdong, Guangzhou, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.